Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Ивабрадин в клинической практике
Ивабрадин в клинической практике
Сыров А.В. Ивабрадин в клинической практике. Consilium Medicum. 2017; 19 (5): 68–71.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
В статье дана оценка клинических свойств ивабрадина. Уникальность препарата заключается в блокировании тока ионных If-каналов синусового узла. Это приводит к урежению синусового ритма и не влияет на уровень артериального давления, сократимость миокарда и периферическое сопротивление сосудов. Разобраны клинические ситуации, при которых эффективно применение ивабрадина.
Ключевые слова: ивабрадин, синусовая тахикардия, урежение синусового ритма.
Key words: ivabradine, sinus tachycardia, reduction heart rate.
Ключевые слова: ивабрадин, синусовая тахикардия, урежение синусового ритма.
________________________________________________
Key words: ivabradine, sinus tachycardia, reduction heart rate.
Полный текст
Список литературы
1. Bocchi EA, Böhm M, Borer JS et al on behalf of SHIFT investigators. Effect of combining ivabradine and b-blockers: Focus on the use of carvedilol in the SHIFT population. Cardiology 2015; 131: 218–24.
2. Swedberg K, Komajda M, Bohm M et al on behalf of the SHIFT investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376: 875–85.
3. Di Franco A, Sarullo FM, Salerno Y et al. Beta-blockers and ivabradine in chronic heart failure: from clinical trials to clinical practice. Am J Cardiovasc Drugs 2014; 14: 101–10.
4. Yancy CW, Jessup M, Bozkurt B et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. J Am Coll Cardiol 2016. DOI: 10.1016/j.jacc.2016.05.011
5. Fox K, Ford I, Steg G et al, for the BEAUTIFUL investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372 (9641): 807–16.
6. Tardif JC, Ponikowski P, Kahan T, for the ASSOCIATE study investigators. Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J 2009; 30 (5): 540–8.
7. Fox K, Ford I, Steg PG et al, for the SIGNIFY investigators. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med 2014; 371 (12): 1091–9.
8. Martin R, Pogoryelova O, Santibáñex Koreg M et al. Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomized controlled trials. Heart 2014; 100: 1506–10.
9. Сыров А.В., Стуров Н.В. Идиопатическая синусовая тахикардия. Трудный пациент. 2015; 7: 21–4. / Syrov A.V., Sturov N.V. Idiopaticheskaia sinusovaia takhikardiia. Trudnyi patsient. 2015; 7: 21–4. [in Russian]
10. Hersi AS. Potentially new indication of ivabradine: treatment of a patient with postural orthostatic tachycardia syndrome. Open Cardiovasc Med 2010; 4: 166–7.
11. Raj SR. Postural tachycardia syndrome (POTS). Circulation 2013; 127: 2336–42.
12. Benezet-Mazuecos J, Rubio JM, Farre J et al. Long-term outcomes of ivabradine in inappropriate sinus tachycardia patients: appropriate efficacy or inappropriate patients. PACE 2013; 36: 830–6.
13. Calo L, Rebecchi M, Sette A et al. Efficacy of ivabradine administration in patients affected by inappropriate sinus tachycardia. Heart Rhythm 2010; 7: 1318–23.
14. Cappato R, Castelvecchio S, Ricci C et al. Clinical efficacy of ivabradine in patients with inappropriate sinus tachycardia: a prospective, randomized, placebo-controlled, double-blind, crossover evaluation. J Am Coll Cardiol 2012; 60: 1323–9.
15. Retegui G, Quintero M, Ruiz-Borrell M, Revello A. Ivabradine as a treatment option for inappropriate sinus tachycardia. Rev Esp Cardiol 2009; 62: 576–88.
16. Babu K, Gadzik F, Holgate S. Absence of respiratory effects with ivabradine in patients with asthma. BJ of Clin Pharm 2008; 66: 96–101.
17. Kim BH, Cho KI, Kim SM et al. Heart rate reduction with ivabradine prevents thyroid hormone-induced cardiac remodeling in rat. Heart Vessels 2013; 28 (4): 524–35.
18. Celik O, Atasoy MM, Ertürk M et al. Single dose ivabradine versus intravenous metoprolol for heart rate reduction before coronary computed tomography angiography (CCTA) in patients receiving long-term calcium channel-blocker therapy. Acta Radiol 2014; 55: 676–81.
19. Pichler P, Pichler-Cetin E, Vertesich M at al. Ivabradine versus metoprolol for heart rate reduction before coronary computed tomography angiography. Am J Cardiol 2012; 109: 169–73.
2. Swedberg K, Komajda M, Bohm M et al on behalf of the SHIFT investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376: 875–85.
3. Di Franco A, Sarullo FM, Salerno Y et al. Beta-blockers and ivabradine in chronic heart failure: from clinical trials to clinical practice. Am J Cardiovasc Drugs 2014; 14: 101–10.
4. Yancy CW, Jessup M, Bozkurt B et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. J Am Coll Cardiol 2016. DOI: 10.1016/j.jacc.2016.05.011
5. Fox K, Ford I, Steg G et al, for the BEAUTIFUL investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372 (9641): 807–16.
6. Tardif JC, Ponikowski P, Kahan T, for the ASSOCIATE study investigators. Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J 2009; 30 (5): 540–8.
7. Fox K, Ford I, Steg PG et al, for the SIGNIFY investigators. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med 2014; 371 (12): 1091–9.
8. Martin R, Pogoryelova O, Santibáñex Koreg M et al. Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomized controlled trials. Heart 2014; 100: 1506–10.
9. Syrov A.V., Sturov N.V. Idiopaticheskaia sinusovaia takhikardiia. Trudnyi patsient. 2015; 7: 21–4. [in Russian]
10. Hersi AS. Potentially new indication of ivabradine: treatment of a patient with postural orthostatic tachycardia syndrome. Open Cardiovasc Med 2010; 4: 166–7.
11. Raj SR. Postural tachycardia syndrome (POTS). Circulation 2013; 127: 2336–42.
12. Benezet-Mazuecos J, Rubio JM, Farre J et al. Long-term outcomes of ivabradine in inappropriate sinus tachycardia patients: appropriate efficacy or inappropriate patients. PACE 2013; 36: 830–6.
13. Calo L, Rebecchi M, Sette A et al. Efficacy of ivabradine administration in patients affected by inappropriate sinus tachycardia. Heart Rhythm 2010; 7: 1318–23.
14. Cappato R, Castelvecchio S, Ricci C et al. Clinical efficacy of ivabradine in patients with inappropriate sinus tachycardia: a prospective, randomized, placebo-controlled, double-blind, crossover evaluation. J Am Coll Cardiol 2012; 60: 1323–9.
15. Retegui G, Quintero M, Ruiz-Borrell M, Revello A. Ivabradine as a treatment option for inappropriate sinus tachycardia. Rev Esp Cardiol 2009; 62: 576–88.
16. Babu K, Gadzik F, Holgate S. Absence of respiratory effects with ivabradine in patients with asthma. BJ of Clin Pharm 2008; 66: 96–101.
17. Kim BH, Cho KI, Kim SM et al. Heart rate reduction with ivabradine prevents thyroid hormone-induced cardiac remodeling in rat. Heart Vessels 2013; 28 (4): 524–35.
18. Celik O, Atasoy MM, Ertürk M et al. Single dose ivabradine versus intravenous metoprolol for heart rate reduction before coronary computed tomography angiography (CCTA) in patients receiving long-term calcium channel-blocker therapy. Acta Radiol 2014; 55: 676–81.
19. Pichler P, Pichler-Cetin E, Vertesich M at al. Ivabradine versus metoprolol for heart rate reduction before coronary computed tomography angiography. Am J Cardiol 2012; 109: 169–73.
2. Swedberg K, Komajda M, Bohm M et al on behalf of the SHIFT investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376: 875–85.
3. Di Franco A, Sarullo FM, Salerno Y et al. Beta-blockers and ivabradine in chronic heart failure: from clinical trials to clinical practice. Am J Cardiovasc Drugs 2014; 14: 101–10.
4. Yancy CW, Jessup M, Bozkurt B et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. J Am Coll Cardiol 2016. DOI: 10.1016/j.jacc.2016.05.011
5. Fox K, Ford I, Steg G et al, for the BEAUTIFUL investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372 (9641): 807–16.
6. Tardif JC, Ponikowski P, Kahan T, for the ASSOCIATE study investigators. Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J 2009; 30 (5): 540–8.
7. Fox K, Ford I, Steg PG et al, for the SIGNIFY investigators. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med 2014; 371 (12): 1091–9.
8. Martin R, Pogoryelova O, Santibáñex Koreg M et al. Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomized controlled trials. Heart 2014; 100: 1506–10.
9. Сыров А.В., Стуров Н.В. Идиопатическая синусовая тахикардия. Трудный пациент. 2015; 7: 21–4. / Syrov A.V., Sturov N.V. Idiopaticheskaia sinusovaia takhikardiia. Trudnyi patsient. 2015; 7: 21–4. [in Russian]
10. Hersi AS. Potentially new indication of ivabradine: treatment of a patient with postural orthostatic tachycardia syndrome. Open Cardiovasc Med 2010; 4: 166–7.
11. Raj SR. Postural tachycardia syndrome (POTS). Circulation 2013; 127: 2336–42.
12. Benezet-Mazuecos J, Rubio JM, Farre J et al. Long-term outcomes of ivabradine in inappropriate sinus tachycardia patients: appropriate efficacy or inappropriate patients. PACE 2013; 36: 830–6.
13. Calo L, Rebecchi M, Sette A et al. Efficacy of ivabradine administration in patients affected by inappropriate sinus tachycardia. Heart Rhythm 2010; 7: 1318–23.
14. Cappato R, Castelvecchio S, Ricci C et al. Clinical efficacy of ivabradine in patients with inappropriate sinus tachycardia: a prospective, randomized, placebo-controlled, double-blind, crossover evaluation. J Am Coll Cardiol 2012; 60: 1323–9.
15. Retegui G, Quintero M, Ruiz-Borrell M, Revello A. Ivabradine as a treatment option for inappropriate sinus tachycardia. Rev Esp Cardiol 2009; 62: 576–88.
16. Babu K, Gadzik F, Holgate S. Absence of respiratory effects with ivabradine in patients with asthma. BJ of Clin Pharm 2008; 66: 96–101.
17. Kim BH, Cho KI, Kim SM et al. Heart rate reduction with ivabradine prevents thyroid hormone-induced cardiac remodeling in rat. Heart Vessels 2013; 28 (4): 524–35.
18. Celik O, Atasoy MM, Ertürk M et al. Single dose ivabradine versus intravenous metoprolol for heart rate reduction before coronary computed tomography angiography (CCTA) in patients receiving long-term calcium channel-blocker therapy. Acta Radiol 2014; 55: 676–81.
19. Pichler P, Pichler-Cetin E, Vertesich M at al. Ivabradine versus metoprolol for heart rate reduction before coronary computed tomography angiography. Am J Cardiol 2012; 109: 169–73.
________________________________________________
2. Swedberg K, Komajda M, Bohm M et al on behalf of the SHIFT investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376: 875–85.
3. Di Franco A, Sarullo FM, Salerno Y et al. Beta-blockers and ivabradine in chronic heart failure: from clinical trials to clinical practice. Am J Cardiovasc Drugs 2014; 14: 101–10.
4. Yancy CW, Jessup M, Bozkurt B et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. J Am Coll Cardiol 2016. DOI: 10.1016/j.jacc.2016.05.011
5. Fox K, Ford I, Steg G et al, for the BEAUTIFUL investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372 (9641): 807–16.
6. Tardif JC, Ponikowski P, Kahan T, for the ASSOCIATE study investigators. Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J 2009; 30 (5): 540–8.
7. Fox K, Ford I, Steg PG et al, for the SIGNIFY investigators. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med 2014; 371 (12): 1091–9.
8. Martin R, Pogoryelova O, Santibáñex Koreg M et al. Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomized controlled trials. Heart 2014; 100: 1506–10.
9. Syrov A.V., Sturov N.V. Idiopaticheskaia sinusovaia takhikardiia. Trudnyi patsient. 2015; 7: 21–4. [in Russian]
10. Hersi AS. Potentially new indication of ivabradine: treatment of a patient with postural orthostatic tachycardia syndrome. Open Cardiovasc Med 2010; 4: 166–7.
11. Raj SR. Postural tachycardia syndrome (POTS). Circulation 2013; 127: 2336–42.
12. Benezet-Mazuecos J, Rubio JM, Farre J et al. Long-term outcomes of ivabradine in inappropriate sinus tachycardia patients: appropriate efficacy or inappropriate patients. PACE 2013; 36: 830–6.
13. Calo L, Rebecchi M, Sette A et al. Efficacy of ivabradine administration in patients affected by inappropriate sinus tachycardia. Heart Rhythm 2010; 7: 1318–23.
14. Cappato R, Castelvecchio S, Ricci C et al. Clinical efficacy of ivabradine in patients with inappropriate sinus tachycardia: a prospective, randomized, placebo-controlled, double-blind, crossover evaluation. J Am Coll Cardiol 2012; 60: 1323–9.
15. Retegui G, Quintero M, Ruiz-Borrell M, Revello A. Ivabradine as a treatment option for inappropriate sinus tachycardia. Rev Esp Cardiol 2009; 62: 576–88.
16. Babu K, Gadzik F, Holgate S. Absence of respiratory effects with ivabradine in patients with asthma. BJ of Clin Pharm 2008; 66: 96–101.
17. Kim BH, Cho KI, Kim SM et al. Heart rate reduction with ivabradine prevents thyroid hormone-induced cardiac remodeling in rat. Heart Vessels 2013; 28 (4): 524–35.
18. Celik O, Atasoy MM, Ertürk M et al. Single dose ivabradine versus intravenous metoprolol for heart rate reduction before coronary computed tomography angiography (CCTA) in patients receiving long-term calcium channel-blocker therapy. Acta Radiol 2014; 55: 676–81.
19. Pichler P, Pichler-Cetin E, Vertesich M at al. Ivabradine versus metoprolol for heart rate reduction before coronary computed tomography angiography. Am J Cardiol 2012; 109: 169–73.
Авторы
А.В.Сыров
ГБУЗ «Консультативно-диагностический центр №6» Департамента здравоохранения г. Москвы. 127474, Россия, Москва, Керамический пр., д. 49б
syrman2002_1@yahoo.com
Advisory-Diagnostic Center №6 of the Department of Health of Moscow. 127474, Russian Federation, Moscow, Keramicheskii pr., d. 49b
syrman2002_1@yahoo.com
ГБУЗ «Консультативно-диагностический центр №6» Департамента здравоохранения г. Москвы. 127474, Россия, Москва, Керамический пр., д. 49б
syrman2002_1@yahoo.com
________________________________________________
Advisory-Diagnostic Center №6 of the Department of Health of Moscow. 127474, Russian Federation, Moscow, Keramicheskii pr., d. 49b
syrman2002_1@yahoo.com
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.